1Rajkumar SV,Blood E,Vesole D, et al. Phase Ⅲ clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma:a clinical trial coordinated by the Eastern Cooperative Oncology Group [ J ]. J Clin Oncol, 2006,24 (3):431 -436.
2Goldschmidt H, Sonnevel P, Breitkreuz I, et al. HOVON50/GMMG- HD3-Trial: Phase Ⅲ study on the effect of thalidomide combined with high dose melphalan in myeloma patients up to 65 years [ J ]. Blood ,2005,106( 11 ) : Abstract 57.
3Wang M, Delasalle K, Giralt S, et al. Rapid control of previously untreated multiple myeloma with bortezomib-thalidomide-dexamethasone followed by early intensive therapy [ J]. Blood,2005,106 ( 11 ) : 784.
4Attal M, Harousseau JL, Leyvraz S, et al. For the Intergroupe Francophone du Myelome (IFM). Maintenance therapy with thalidomide improves survival in patients with multiple myeloma [ J ]. Blood, 2006, 108(10) : 3289 -3294.
5Bajkumar SV, Hayman SB, Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone (Bev/Dex) for newly diagnosed myeloma [ J ]. Blood, 2005, 106 ( 13 ) : 4050 - 4053.
6Niesvizky R,Pekh K,Gelbshtein U,et al. BIRD( Biaxin/Revlimid/ Dexame-thasone) combination therapy(Rx) results in high complete remissions (CR) and overall responses in myeloma(MM) with poor prognostic features[ J ]. Blood, 2005, 106 ( 11 ) : 642.
3Michihide Tokuhira,Atsushi Iizuka,Reiko Watanabe,Naoya Sekiguchi,Norihide Sato,Chen-Kang Chien,Yasunobu Sekiguchi,Tomoe Nemoto,Kyoko Hanzawa,Jun-ichi Tamaru,Shinji Itoyama,Hiroshi Suzuki,Tsutomu Takeuchi,Shigehisa Mori,Masahiro Kizaki.Severe degenerative change of multiple organs mediated by chronic active Epstein–Barr virus infection with infected T-cell expansion[J]. International Journal of Hematology . 2008 (5)
4Masao Hagihara,Takahide Tsuchiya,Osamu Hyodo,Yoko Ueda,Kei Tazume,Aya Masui,Ayako Kanemura,Fumiaki Yoshiba,Shinji Takashimizu,Shohei Matzusaki,Shunichi Kato,Tomomitsu Hotta.Clinical effects of infusing anti-epstein-barr virus (EBV)-specific cytotoxic T-lymphocytes into patients with severe chronic active EBV infection[J]. International Journal of Hematology . 2003 (1)
5Tsai MH,Hsu CY,Yen MH,et al.Epstein-Barr virus-associated infectious mononucleosis and risk factor analysis for complications in hospitalized children. Journal of Microbiology Immunology and Infection . 2005
6Bell A T,Fortune B,Sheeler R.Clinical inquiries. What test in the best for diagnosing infectious mononucleosis. Journal of Family Practice . 2006
7Hurt C,Tammaro D.Diagnostic evaluation of mononucleosis-like illnesses. The American Journal of Medicine . 2007
8Straus SE.The chronic mononucleosis syndrome. The Journal of Infectious Diseases . 1988
9M Okano,K Kawa,H Kimura,A Yachie,H Wakiguchi,A Maeda,S Imai,S Ohga,H Kanegane,S Tsuchiya,T Morio,M Mori,S Yokota,S Imashuku.Proposed guidelines for diagnosing chronic active Epstein–Barr virus infection. American Journal of Hematology . 2005
10Kimura H,Hoshino Y,Hara S,et al.Differences between T cell-type;and natural killer cell-type chronic active Apstein-Barr virus infection. The Journal of Infectious Diseases . 2005
